Trial Profile
Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients With Clinical Evidence for Non-alcoholic Fatty Liver Disease (NAFLD): Supporting the Disease Staging Into Fatty Liver Disease Versus Non-alcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2015
Price :
$35
*
At a glance
- Drugs Cholyl lysyl fluorescein (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Diagnostic use
- Sponsors Norgine
- 21 May 2014 New trial record